Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8527 PK in Renal Impairment
NCT06295796Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mk-8527 in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration Versus Time Curve From Time 0 to Last Quantifiable Sample of MK-8527 in Plasma at 168 hours, Area Under the Concentration Versus Time Curve From Time 0 to Infinity of MK-8527 in Plasma at 168 hours and 4 more. Started Jun 2024; status: completed.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06295796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06295796.